Skip to main content
Home
Browse topics
Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring
Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Cardiovascular disorders


Browse the latest news, expert commentary, and educational content on cardiovascular disorders.


Highlights

18-11-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

08-11-2022 | SGLT2 inhibitors | News

Meta-analysis backs SGLT2 inhibitors for kidney disease

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

21-10-2022 | Cardiovascular disorders | News

Diabetes ‘no longer a CVD risk equivalent’

The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.

More on cardiovascular disorders

25-09-2023 | Gestational diabetes | News

Gestational diabetes independently linked to increased future mortality risk

20-09-2023 | Latent autoimmune diabetes of adulthood | News

Latent autoimmune diabetes carries mortality and CVD risks comparable to type 2 diabetes

31-08-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

07-07-2023 | Type 2 diabetes | News

New atherothrombotic risk score for type 2 diabetes

22-06-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

21-06-2023 | Cardiovascular disorders | News

Non-fasting remnant cholesterol shows mixed prognostic value for CVD by diabetes status

24-04-2023 | Heart failure | News

Prescription NSAID use may trigger heart failure in type 2 diabetes

24-04-2023 | Sulfonylureas | News

Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

10-03-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

08-02-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure
Image Credits